In March 2017 the Innovative Medicines Initiative (IMI) launched a new project on cardiovascular disease to show how big data can drive progress in the CVD treatment and management.
BigData@Heart is a 5-year, € 19 million project supported by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European pharmaceutical industry. The BigData@Heart consortium, consisting of 19 partners coming from academia, medical associations, pharmaceutical industry, SMEs and patient organisations and led by Prof. Diederick E. (Rick) Grobbee from the University Medical Center Utrecht (UMCU) and Dr. Gunnar Brobert from Bayer, will develop a data-driven translational research platform, which will be aiming at delivering clinically relevant disease phenotypes, scalable insights from real-world evidence, best-practices in drug development, and personalised medicines through advanced analytics.
This project will develop and test a framework that will enable big data driven cardiovascular research, including the development of:
Better understanding of heart disease, the development of new therapy targets, improved drug and device development/utilisation, and laying a scientific foundation for progress in the personalised treatment and management of CVD are among the expected impact of BigData@Heart on science, industry, policies and patients.
Further information can be found on the project website.
